Skip to main content

siranaomics logo

GAITHERSBURG, Md. and SUZHOU BIOBAY, China, July 1, 2021 /PRNewswire/ — Sirnaomics Ltd., a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today that it has sealed $105 million in a Series E financing.  This round of funding was led by Rotating Boulder Fund, an investor that has been supporting the company since its Series B round, with participation from existing investors and a well-recognized syndicate of new investors.

 

{iframe}https://biobuzz.io/gaithersburgs-sirnaomics-secures-105-million-in-series-e-financing-to-fund-development-of-novel-rnai-therapeutics/{/iframe}

Search

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.